In 1982, the U.S. approved human insulin—the first ever recombinant biopharmaceutical drug. Since then, biopharma development has proceeded at an exponential pace, with new innovations redefining, over and over again, the possibilities of medicine. Going forward, biopharma will demand more
Biopharmaceuticals are among the most complex and elegant realizations of modern science. But this complexity also comes at great cost. More exactly, biotech-manufacturing facilities need between $200 and $500 million to be built and this process could last up to five years. The Challenges of
